Latest Articles

Publication Date
Chronic Pelvic Pain in Women: Evaluation and Treatment.

Chronic pelvic pain affects up to 26% of individuals with female anatomy and is defined as at least 6 months of pain that is perceived to originate in the pelvis. …

Published: March 20, 2025, midnight
Health Canada Approves KEYTRUDA® for the Treatment of Adult Patients with Primary Advanced or Recurrent Endometrial Carcinoma, in Combination with Carboplatin and Paclitaxel and then Continued as Monotherapy - The Malaysian Reserve

Health Canada Approves KEYTRUDA® for the Treatment of Adult Patients with Primary Advanced or Recurrent Endometrial Carcinoma, in Combination with Carboplatin and Paclitaxel and then Continued as Monotherapy The Malaysian …

Published: March 19, 2025, 10:53 p.m.
NHS approval of endometriosis therapy Ryeqo enhances patient care - The Hippocratic Post

NHS approval of endometriosis therapy Ryeqo enhances patient care The Hippocratic Post

Published: March 19, 2025, 12:01 p.m.
Health Canada Approves KEYTRUDA® for the Treatment of Adult Patients with Primary Advanced or Recurrent Endometrial Carcinoma, in Combination with Carboplatin and Paclitaxel and then Continued as Monotherapy - Weekly Voice

Health Canada Approves KEYTRUDA® for the Treatment of Adult Patients with Primary Advanced or Recurrent Endometrial Carcinoma, in Combination with Carboplatin and Paclitaxel and then Continued as Monotherapy Weekly Voice

Published: March 19, 2025, 11:20 a.m.
Health Canada Approves KEYTRUDA® for the Treatment of Adult Patients with Primary Advanced or Recurrent Endometrial Carcinoma, in Combination with Carboplatin and Paclitaxel and then Continued as Monotherapy - Yahoo Canada Finance

Health Canada Approves KEYTRUDA® for the Treatment of Adult Patients with Primary Advanced or Recurrent Endometrial Carcinoma, in Combination with Carboplatin and Paclitaxel and then Continued as Monotherapy Yahoo Canada …

Published: March 19, 2025, 11 a.m.
Health Canada Approves KEYTRUDA® for the Treatment of Adult Patients with Primary Advanced or Recurrent Endometrial Carcinoma, in Combination with Carboplatin and Paclitaxel and then Continued as Monotherapy - Yahoo Finance

Health Canada Approves KEYTRUDA® for the Treatment of Adult Patients with Primary Advanced or Recurrent Endometrial Carcinoma, in Combination with Carboplatin and Paclitaxel and then Continued as Monotherapy Yahoo Finance

Published: March 19, 2025, 11 a.m.
Targeting ferroptosis for the treatment of female reproductive system disorders.

Ferroptosis, a regulated form of cell death driven by iron-dependent lipid peroxidation, has emerged as a critical factor in female reproductive health and has been implicated in disorders such as …

Published: March 18, 2025, midnight
Endogenous Causes of Obturator Nerve Entrapment: Literature Review and Proposal of a Treatment Algorithm.

Background: Obturator nerve entrapment can result from endogenous and exogenous causes. Due to its long course, which includes both endopelvic and exopelvic segments, the nerve is susceptible to irritation from …

Published: March 18, 2025, midnight
Lenvatinib plus pembrolizumab not associated with improved survival compared to standard therapy for recurrent endometrial cancer - 2 Minute Medicine

Lenvatinib plus pembrolizumab not associated with improved survival compared to standard therapy for recurrent endometrial cancer 2 Minute Medicine

Published: March 17, 2025, 11:07 p.m.
Real-World Analysis Confirms Efficacy/Safety of Dostarlimab Plus Chemotherapy in Advanced Endometrial Cancer - OncLive

Real-World Analysis Confirms Efficacy/Safety of Dostarlimab Plus Chemotherapy in Advanced Endometrial Cancer OncLive

Published: March 17, 2025, 9:22 p.m.
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!